Translational Stroke Research: Vision and Opportunities

@article{Bosetti2017TranslationalSR,
  title={Translational Stroke Research: Vision and Opportunities},
  author={Francesca Bosetti and James I. Koenig and Cenk Ayata and Stephen A. Back and Kyra J. Becker and Joseph P. Broderick and S. Thomas Carmichael and Sunghee Cho and Marilyn J. Cipolla and Dale Corbett and Roderick A. Corriveau and Steven C. Cramer and Adam R Ferguson and Seth P. Finklestein and Byron D. Ford and Karen L. Furie and Thomas M. Hemmen and Costantino Iadecola and Lyn B. Jakeman and Scott Janis and Edward C. Jauch and Karen C. Johnston and Patrick M. Kochanek and Harold L Kohn and Eng H. Lo and Patrick D. Lyden and Carina Mallard and Louise D. McCullough and Linda Mcgavern and James F. Meschia and Claudia Scala Moy and Miguel A. Perez-Pinzon and Ipolia Ramadan and Sean Isaac Savitz and Lee H. Schwamm and Gary K. Steinberg and Mary P. Stenzel-Poore and Michael Tymianski and Steven J. Warach and Lawrence R. Wechsler and John H. Zhang and Walter J. Koroshetz},
  journal={Stroke},
  year={2017},
  volume={48},
  pages={2632–2637}
}
See related article, p 2341 Stroke risk and poststroke disability have steadily decreased in the United States over the past 2 decades because of improved prevention and access to reperfusion therapies for acute ischemic stroke, such as tPA (tissue-type plasminogen activator; alteplase) and endovascular thrombectomy. Despite the efficacy and safety of thrombolysis and thrombectomy, not all patients who receive the treatment improve to full, independent recovery, and most patients are… 

Translational Stroke Research Review: Using the Mouse to Model Human Futile Recanalization and Reperfusion Injury in Ischemic Brain Tissue

TLDR
It is suggested that stroke preclinical research should increasingly drive forward a continuous and circular dialogue with clinical research and that when the preclinical and the clinical stroke research are consistent, translational success will follow.

Advancement in stroke research

TLDR
The 2nd Summit of Chinese Basic Science Research on Stroke 2018 has been held in Beijing, China and focused on six fields on neuroprotection in acute ischaemic stroke, neuroinflammation and neuroimmunology, drug/small molecule therapy for stroke; and (6) advances in optical imaging.

Cerebroprotection for Acute Ischemic Stroke

TLDR
Success in developing cerebroprotection-either as an adjunct to recanalization or as stand-alone treatment-will require new definitions that recognize the importance of differential vulnerability in the neurovascular unit, and the prospect for successful cerebroprotective therapy should improve.

Towards Improved Translational Stroke Research: Progress and Perspectives of the Recent National Institute of Neurological Disorders and Stroke Consensus Group Meeting

TLDR
In this issue of Stroke, a National Institute of Neurological Disorders and Stroke consensus group comprising leading academic, industry, and Food and Drug Administration experts working at the forefront of stroke research has recently published guidelines for improved translational studies.

The neurovascular unit and systemic biology in stroke — implications for translation and treatment

TLDR
The authors summarize the interactions of the neurovascular unit with systemic biology after ischaemic stroke, consider how these interactions influence stroke outcome, and discuss howThese interactions could be targeted to improve outcomes.

The future of neuroprotection in stroke

TLDR
A deeper knowledge of the mechanisms involved in the ischaemic death process at the neurovascular unit, an improved preselection and evaluation of drugs at the preclinical stage and the testing of putative neuroprotectants in enriched clinical studies of patients receiving reperfusion therapies, might prove more effective than in the past to reverse a dismal situation that has lasted already too long.

Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke

TLDR
In conclusion, ML351 and tPA combination therapy is beneficial in ameliorating HT after ischemic stroke and probably because of 12/15‐LOX inhibition and suppression of JNK‐mediated microglia/macrophage activation.

A Narrative Review on Translational Research in Acute Brain Injury

TLDR
The major hurdles in the translation of preclinical results into clinical practice are discussed, keeping in mind the species, age, and gender of the animal, choosing suitable outcome measures, ensuring quality of animal trials, and carrying out systematic review and meta-analysis of experimental studies before proceeding to human trials.

The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results

TLDR
The data suggest that a large, multilaboratory, preclinical assessment effort to reduce known sources of bias is feasible and practical.
...

References

SHOWING 1-10 OF 31 REFERENCES

Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials

TLDR
New suggestions to bridge the chasm between preclinical animal modeling and acute human stroke trials to potentially enhance the future assessment of novel neuroprotective drugs are discussed.

A randomized trial of intraarterial treatment for acute ischemic stroke.

TLDR
In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe.

Preclinical Drug Evaluation for Combination Therapy in Acute Stroke Using Systematic Review, Meta-Analysis, and Subsequent Experimental Testing

  • V. O'CollinsM. Macleod D. Howells
  • Medicine, Psychology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2011
TLDR
It was concluded that this combination of magnesium sulphate, melatonin, and minocycline, chosen from a library of neuroprotective agents, was not effective in these stroke models.

The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents.

TLDR
It is proposed that the use of modality-specific outcome measures may be best suited as primary end points in clinical trials of stroke recovery-promoting agents and may result in a more selective labeling of strokes recovery treatments.

Evolution of ischemic damage and behavioural deficit over 6 months after MCAo in the rat: Selecting the optimal outcomes and statistical power for multi-centre preclinical trials

TLDR
This study investigates the development of ischemic damage after thread occlusion MCAo in the rat, using histological and behavioural outcomes and the adhesive removal test to investigate the longevity of behavioural deficit after isChemic stroke in rats, and examines the practicality of using such measures as the primary outcome for future studies.

Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy.

TLDR
This review outlines the approach to TBI modeling, evaluation of therapies, drug selection, and biomarker assessments for OBTT, and provides a framework for reports in this issue on the first five therapies evaluated by the consortium.

Development of a database for translational spinal cord injury research.

TLDR
The development of a novel database for translational neurotrauma research known as Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION- SCI) is described and syndromic analysis is used to identify conserved biological mechanisms of recovery after cervical SCI between rats and monkeys.